Vaccitech PLC
F:2AB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vaccitech PLC
Other Non-Cash Items
Vaccitech PLC
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vaccitech PLC
F:2AB
|
Other Non-Cash Items
$13.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Other Non-Cash Items
£16m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Other Non-Cash Items
$144.7m
|
CAGR 3-Years
107%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Other Non-Cash Items
£24.8m
|
CAGR 3-Years
28%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Other Non-Cash Items
£4.2m
|
CAGR 3-Years
40%
|
CAGR 5-Years
1%
|
CAGR 10-Years
19%
|
|
|
Niox Group PLC
LSE:NIOX
|
Other Non-Cash Items
£800k
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
Vaccitech PLC
Glance View
Vaccitech Plc operates as a holding company. The company is headquartered in Oxford, Oxfordshire and currently employs 72 full-time employees. The company went IPO on 2021-04-30. The firm is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The firm uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The firm has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).
See Also
What is Vaccitech PLC's Other Non-Cash Items?
Other Non-Cash Items
13.2m
USD
Based on the financial report for Dec 31, 2025, Vaccitech PLC's Other Non-Cash Items amounts to 13.2m USD.
What is Vaccitech PLC's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 5Y
23%
Over the last year, the Other Non-Cash Items growth was -45%.
